Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

被引：0

作者：

Hui Yu

Ping Chen

Xiuyu Cai

Chen Chen

Xuanye Zhang

Lina He

Yixin Zhou

Shaodong Hong

Bei Zhang

机构：

[1] State Key Laboratory of Oncology in South China,Department of VIP Region

[2] Collaborative Innovation Center for Cancer Medicine,Department of Radiotherapy

[3] Sun Yat-Sen University Cancer Center,Department of Medical Oncology

[4] Sun Yat-Sen University Cancer Center,undefined

[5] Sun Yat-Sen University Cancer Center,undefined

来源：

Cancer Immunology, Immunotherapy | 2022年 / 71卷

关键词：

PD-L1 inhibitors; PD-1 inhibitors; Small-cell lung cancer; First-line therapy; Efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：637 / 644

页数：7

共 50 条

[21] Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung cancer: A network meta-analysis
Liu, Liyan
Yan, Yilong
Wang, Yuqiao
Li, Ziming
Yang, Li
Yu, Kefu
Zhao, Zhigang
ONCOLOGY LETTERS, 2025, 29 (03)
[22] EFFICACY OF PD1/PD-L1 INHIBITORS VS CHEMOTHERAPY AS FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS WITH DIFFERENT PD-L1 EXPRESSION LEVELS
Lin, G.
Lingohr-Smith, M.
Deitelzweig, C.
Lin, J.
VALUE IN HEALTH, 2022, 25 (07) : S318 - S318
[23] Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
Shen, Kaikai
Cui, Jinggang
Wei, Yuqing
Chen, Xiaojun
Liu, Guohua
Gao, Xiaolai
Li, Wei
Lu, Huiling
Zhan, Ping
Lv, Tangfeng
Lin, Dang
JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6636 - 6652
[24] Delayed addition of PD-1/PD-L1 inhibitors into chemotherapy on the outcomes for patients with extensive-stage small cell lung cancer: A propensity score-matched study.
Lu, Shuangqing
Tian, Yaru
Zhu, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 208 - 208
[25] Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Ando, Koichi
Manabe, Ryo
Kishino, Yasunari
Kusumoto, Sojiro
Yamaoka, Toshimitsu
Tanaka, Akihiko
Ohmori, Tohru
Ohnishi, Tsukasa
Sagara, Hironori
CURRENT ONCOLOGY, 2021, 28 (02) : 1094 - 1113
[26] Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials
Li, Zhi-Qiang
Yan, Hai-Cui
Gu, Jing-Jing
Yang, Yong-Liang
Zhang, Ming-Kui
Fang, Xin-Jian
PHARMACOLOGICAL RESEARCH, 2020, 160
[27] Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China
Teng, Meng-Meng
Chen, Si-Ying
Yang, Bo
Wang, Yan
Han, Rui-Ying
An, Meng-Na
Dong, Ya-lin
You, Hai-Sheng
CANCER MEDICINE, 2021, 10 (18): : 6344 - 6353
[28] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
Qin, Boyu
Xin, Lingli
Liang, Chen
Li, Lingling
Song, Qi
Long, Yaping
Zhang, Xiaoling
Wang, Dan
Shi, Weiwei
Zhang, Jing
Hu, Yi
Yang, Bo
Xiong, Qi
BMC CANCER, 2024, 24 (01)
[29] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
Boyu Qin
Lingli Xin
Chen Liang
Lingling Li
Qi Song
Yaping Long
Xiaoling Zhang
Dan Wang
Weiwei Shi
Jing Zhang
Yi Hu
Bo Yang
Qi Xiong
BMC Cancer, 24
[30] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Wang, Q.
Ma, C.
Wang, T.
Chen, G.
Wang, H.
Mei, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063

← 1 2 3 4 5 →